4 completed, 3 active not recruiting, 2 terminated, 1 not yet recruiting. 6 Phase 2, 3 Early Phase 1, 3 Phase 1, 1 Phase 3.
Follow Metastatic Kidney Carcinoma: new trials by email Literature Review of Metastatic Kidney Carcinoma trials Research Report on Metastatic Kidney Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Mercaptopurine for the Treatment of Hereditary Leiomyomatosis and Renal Cell Carcinoma (HLRCC), Uterine/Cutaneous Leiomyomas, and Kidney Cancer Biopsy Procedure, Biospecimen Collection, Computed Tomography - Advanced Kidney Carcinoma, Advanced Renal Cell Carcinoma | Phase 1 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 18 | 2026-12-01 | 2026-08-06 |
| CARE1 Pragmatic Clinical Trial Nivolumab, Ipilimumab, Pembrolizumab - Metastatic Kidney Cancer, Metastatic Kidney Carcinoma | Phase 3 | Recruiting | Gustave Roussy, Cancer Campus, Grand Paris | 1250 | 2024-04-12 | 2025-01-16 |
| 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Early Phase 1 | Completed | University of Southern California | 10 | 2021-02-15 | 2024-05-24 |
| Daratumumab in Treating Patients with Muscle Invasive Bladder Cancer or Metastatic Kidney Cancer Biopsy, Daratumumab, Laboratory Biomarker Analysis - Bladder Urothelial Carcinoma, Clear Cell Renal Cell Carcinoma | Early Phase 1 | Completed | M.D. Anderson Cancer Center | 17 | 2018-05-29 | 2025-01-30 |
| Image Guided Hypofractionated Radiation Therapy, Nelfinavir Mesylate, Pembrolizumab, Nivolumab and Atezolizumab in Treating Patients With Advanced Melanoma, Lung, or Kidney Cancer Atezolizumab, Hypofractionated Radiation Therapy, Laboratory Biomarker Analysis - Metastatic Kidney Carcinoma, Recurrent Lung Non-Small Cell Carcinoma | Phase 2 | Terminated | University of Washington | 21 | 2017-06-09 | 2022-06-22 |
| Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment - Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 42 | 2017-04-23 | 2024-11-19 |
| Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord Computed Tomography, Quality-of-Life Assessment, Questionnaire Administration - Malignant Digestive System Neoplasm, Metastatic Head and Neck Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 60 | 2016-08-29 | 2026-10-07 |
| Nivolumab With or Without Bevacizumab or Ipilimumab Before Surgery in Treating Patients With Metastatic Kidney Cancer That Can Be Removed by Surgery Bevacizumab, Biopsy, Ipilimumab - Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Early Phase 1 | Active not recruiting | M.D. Anderson Cancer Center | 104 | 2014-11-25 | 2026-06-01 |
| Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Cabozantinib S-malate, Laboratory Biomarker Analysis, Sunitinib Malate - Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 157 | 2013-07-08 | 2021-02-11 |
| Akt Inhibitor MK2206 or Everolimus in Treating Patients With Refractory Kidney Cancer Akt Inhibitor MK2206, Everolimus, Laboratory Biomarker Analysis - Metastatic Kidney Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Terminated | National Cancer Institute (NCI) | 43 | 2011-01-27 | 2019-10-10 |
| Entinostat in Combination With Aldesleukin in Treating Patients With Metastatic Kidney Cancer Aldesleukin, Computed Tomography, Entinostat - Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 47 | 2009-10-29 | 2026-08-13 |
Carcinoma, Renal Cell (11) · Melanoma (3) · Brain Neoplasms (1) · Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Colonic Neoplasms (1) · Gastrointestinal Neoplasms (1) · Glioma (1) · Hereditary leiomyomatosis and renal cell cancer (1) · Kidney Neoplasms (1) · Lung Neoplasms (1) · Myofibroma (1) · Neoplasms, Unknown Primary (1) · Sarcoma (1) · Spinal Cord Compression (1)
Adenocarcinoma (11) · Carcinoma (11) · Female Urogenital Diseases (11) · Female Urogenital Diseases and Pregnancy Complications (11) · Kidney Diseases (11) · Male Urogenital Diseases (11) · Neoplasms (11) · Neoplasms by Histologic Type (11) · Neoplasms by Site (11) · Neoplasms, Glandular and Epithelial (11) · Urogenital Diseases (11) · Urogenital Neoplasms (11) · Urologic Diseases (11) · Kidney Neoplasms (10) · Urologic Neoplasms (10)
Nivolumab (4) · Biopsy (3) · Magnetic Resonance Spectroscopy (3) · Ipilimumab (2) · Metastasectomy (2) · cabozantinib (2) · pembrolizumab (2) · Axitinib (1) · Bevacizumab (1) · CTLA-4 Antigen (1) · Disulfides (1) · Everolimus (1) · Fluorodeoxyglucose F18 (1) · Immunoglobulin G (1) · MK 2206 (1)
M.D. Anderson Cancer Center (4) · National Cancer Institute (NCI) (3) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Jonsson Comprehensive Cancer Center (1) · University of Southern California (1) · University of Washington (1)
United States (10) · Austria (1) · Czechia (1) · France (1) · Netherlands (1)
Brian Shuch (1) · Eric Jonasch (1) · Hossein Jadvar, MD (1) · Jing Li (1) · Matthew T Campbell (1) · Padmanee Sharma (1) · Pavlos Msaoel (1) · Ramesh Rengan (1) · Saby George (1) · Toni K Choueiri (1)
PMID 28549224, PMID 29550566, PMID 31371341, PMID 31399500, PMID 37146227
P30CA016672 (3), 2023 (1), N01CM00038 (1), N01CM00039 (1), N01CM62202 (1), P30CA014089 (1), P30CA015704 (1), P30CA016056 (1), R21CA137649 (1), U01CA062505 (1), U01CA070095 (1), U01CA076576 (1), U10CA031946 (1), U10CA180821 (1), UM1CA186691 (1)